AVCN.TO Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 09:48):

Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research and development of evidence-based products for consumer medical and pharmaceutical segments worldwide...

Stats
Today's Volume	6 520.00
Average Volume	107 882
Market Cap	30.25M
EPS	$0 ( 2024-04-01 )
Next earnings date	( $0 ) 2024-05-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.03
ATR14	$0.00500 (1.45%)

AVICANNA INC Correlation

10 Most Positive Correlations
SJR-B.TO	0.846
HGRO.TO	0.846
CEU.TO	0.845
SSF-UN.TO	0.841
MDA.TO	0.841
NVCN.TO	0.834
OLY.TO	0.827
PFMN.TO	0.827
HSAV.TO	0.82
LAM.TO	0.81

10 Most Negative Correlations
SOY.TO	-0.908
IMV.TO	-0.868
PET.TO	-0.863
QSR.TO	-0.861
IMP.TO	-0.853
HUT.TO	-0.833
AII.TO	-0.83
EXE.TO	-0.828
CGY.TO	-0.825
HLF.TO	-0.824

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

AVICANNA INC Financials

Annual	2023
Revenue:	$16.79M
Gross Profit:	$6.58M (39.20 %)
EPS:	$-0.0931

FY	2023
Revenue:	$16.79M
Gross Profit:	$6.58M (39.20 %)
EPS:	$-0.0931

FY	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$0

FY	2022
Revenue:	$4.05M
Gross Profit:	$1.12M (27.55 %)
EPS:	$-0.290

Financial Reports:

No articles found.

AVICANNA INC

Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research and development of evidence-based products for consumer medical and pharmaceutical segments worldwide. The company collaborates with Canadian academic and medical institutions. Its scientific platform includes research and development, and clinical development that leads to the commercialization of approximately twenty products across four main market segments. The company provides medical and wellness products containing cannabidiol, cannabigerol, and tetrahydrocannabinol under the RHO Phyto brand; functional CBD consumer derma-cosmetic and topical products under the Pura H&W and Pura Earth brand names; and cannabis dried flowers, standardized seeds, full spectrum extracts, cannabinoid distillates, isolated cannabinoids, and bulk formulations derived from hemp and cannabis cultivars under the Aureus brand. It also develops pharmaceutical products for epidermolysis bullosa, dermatology, chronic pain, and various neurological disorders. The company has research collaboration with Dr. Christine Allen'sResearch Group for the development of a cannabinoid-based treatment for lung inflammation associated with COVID19. Avicanna Inc. was incorporated in 2016 and is headquartered in Toronto, Canada.